NS Pharma Enters Rare Disease Strategic Alliance with Boston Children’s Hospital

Rare Daily Staff

NS Pharma parent company Nippon Shinyaku has finalized a strategic partnership with Boston Children’s Hospital to support the research and development of innovative therapies for rare diseases.

Under the agreement, Nippon Shinyaku and Boston Children’s will leverage their combined expertise in clinical research and pharmaceutical development to bring more treatment options to patients.

Nippon Shinyaku will assess the Boston Children’s proposals and select those of interest for joint research. Proposals may span a range of developmental stages, from early investigations into the biological mechanisms of rare disease, to the identification of possible therapeutic targets, or the generation and validation of new therapeutic entities.

The company said the agreement was facilitated by the NS Pharma Innovation Research Partnering team, located in Cambridge, Massachusetts.

“Through our strategic alliance with Boston Children’s Hospital, the NS Group will continue to apply advanced medical technology in the field of rare diseases,” said NS Pharma President Yukiteru Sugiyama. “We are excited about the extensive opportunities for innovation derived from this collaboration and the ability to deliver new therapies to patients suffering from these conditions as soon as possible.”